GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims ...

British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

Arexvy and Abrysvo are approved to prevent RSV-associated lower respiratory tract disease in adults aged 50 to 59 and 18 to ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

GSK has been found guilty of bringing discredit on the pharma industry after a complainan | GSK has been found guilty of ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon. The post Were we right to ditch our GSK ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.